AIM ImmunoTech Files 8-K

Ticker: AIM · Form: 8-K · Filed: Feb 11, 2025 · CIK: 946644

Aim Immunotech INC. 8-K Filing Summary
FieldDetail
CompanyAim Immunotech INC. (AIM)
Form Type8-K
Filed DateFeb 11, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, filing, corporate-update

TL;DR

AIM ImmunoTech filed an 8-K on Feb 11, 2025. Standard reporting.

AI Summary

AIM ImmunoTech Inc. filed an 8-K on February 11, 2025, reporting other events and financial statements. The company, formerly known as Hemispherx Biopharma Inc., is incorporated in Delaware and operates in the biological products sector.

Why It Matters

This filing provides an update on AIM ImmunoTech's corporate activities and financial reporting, which is important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically reports on other events or financial statements without disclosing significant new material information.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of February 11, 2025.

When was AIM ImmunoTech Inc. formerly known as?

AIM ImmunoTech Inc. was formerly known as HEMISPHERX BIOPHARMA INC.

In which state is AIM ImmunoTech Inc. incorporated?

AIM ImmunoTech Inc. is incorporated in Delaware.

What is the principal executive office address for AIM ImmunoTech Inc.?

The principal executive offices are located at 2117 SW Highway 484, Ocala, FL 34473.

What is the SIC code for AIM ImmunoTech Inc.?

The Standard Industrial Classification (SIC) code for AIM ImmunoTech Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 644 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2025-02-11 08:35:22

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Date: February 11, 2025 By /s/ Thomas K. Equels Thomas K. Equels, CEO -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing